Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma
Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma
复制标题
DOI：
10.1517/13543776.2014.870155
复制
发表时间：
2014-05-01
影响因子：
6.6
通讯作者：
Norman, Peter
中科院分区：
文献类型：
--
作者：
Norman, Peter
（S）-4-氨基-6-（（1-（5-氯-4-氧代-3-苯基-3，4-二氢喹唑啉-2-基）乙基）氨基）嘧啶-5-甲腈被声称是高选择性的PI 3 K δ抑制剂。据称其可用于治疗哮喘，并且似乎旨在用于口服给药。口服给药后吸收良好，代谢稳定性合理
(S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl) amino) pyrimidine-5-carbonitrile is claimed as a highly selective, PI3K delta inhibitor. It is claimed to be useful in the treatment of asthma and appears intended for oral administration. It is shown to be well absorbed after oral administration and to have reasonable metabolic stability